Ovid Therapeutics Inc. (OVID) stock
OVIDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 10/30
$2.22−0.18 (-7.50%)
Close on Nov 17, 2026Market cap $433.56MP/E –Yield –
Ovid Therapeutics cash
Cash and short-term investments held at the end of each period.
Ovid Therapeutics's cash was $169.77M at Jun 30, 2026. For fiscal 2025 it was $90.45M, up 70.4% from the year before. Over ten years it grew 2.6% a year on average. The highest annual figure on record is $187.80M in fiscal 2021.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $90.45M | +70.4% |
| FY2024 | Dec 31, 2024 | $53.08M | -49.9% |
| FY2023 | Dec 31, 2023 | $105.83M | -18.0% |
| FY2022 | Dec 31, 2022 | $129.00M | -31.3% |
| FY2021 | Dec 31, 2021 | $187.80M | +160.7% |
| FY2020 | Dec 31, 2020 | $72.03M | -6.1% |
| FY2019 | Dec 31, 2019 | $76.70M | +84.8% |
| FY2018 | Dec 31, 2018 | $41.50M | -52.4% |
| FY2017 | Dec 31, 2017 | $87.13M | +67.7% |
| FY2016 | Dec 31, 2016 | $51.94M | -25.7% |
| FY2015 | Dec 31, 2015 | $69.94M | +1343.1% |
| FY2014 | Dec 31, 2014 | $4.85M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $169.77M | +342.7% |
| Q1 FY2026 | Mar 31, 2026 | $165.60M | +285.1% |
| Q4 FY2025 | Dec 31, 2025 | $90.45M | +70.4% |
| Q3 FY2025 | Sep 30, 2025 | $25.60M | -59.2% |
| Q2 FY2025 | Jun 30, 2025 | $38.35M | -50.2% |
| Q1 FY2025 | Mar 31, 2025 | $43.00M | -52.4% |
| Q4 FY2024 | Dec 31, 2024 | $53.08M | -49.9% |
| Q3 FY2024 | Sep 30, 2024 | $62.71M | -28.0% |
| Q2 FY2024 | Jun 30, 2024 | $76.97M | -20.2% |
| Q1 FY2024 | Mar 31, 2024 | $90.26M | -23.3% |
| Q4 FY2023 | Dec 31, 2023 | $105.83M | -18.0% |
| Q3 FY2023 | Sep 30, 2023 | $87.07M | -36.8% |
| Q2 FY2023 | Jun 30, 2023 | $96.52M | -36.7% |
| Q1 FY2023 | Mar 31, 2023 | $117.72M | -30.2% |
| Q4 FY2022 | Dec 31, 2022 | $129.00M | -31.3% |
| Q3 FY2022 | Sep 30, 2022 | $137.86M | -31.7% |
| Q2 FY2022 | Jun 30, 2022 | $152.37M | -28.2% |
| Q1 FY2022 | Mar 31, 2022 | $168.60M | -27.7% |
| Q4 FY2021 | Dec 31, 2021 | $187.80M | +160.7% |
| Q3 FY2021 | Sep 30, 2021 | $201.78M | +132.3% |
| Q2 FY2021 | Jun 30, 2021 | $212.17M | +414.3% |
| Q1 FY2021 | Mar 31, 2021 | $233.05M | +299.7% |
| Q4 FY2020 | Dec 31, 2020 | $72.03M | -6.1% |
| Q3 FY2020 | Sep 30, 2020 | $86.87M | +129.2% |
| Q2 FY2020 | Jun 30, 2020 | $41.25M | -12.9% |
| Q1 FY2020 | Mar 31, 2020 | $58.30M | -2.2% |
| Q4 FY2019 | Dec 31, 2019 | $76.70M | +84.8% |
| Q3 FY2019 | Sep 30, 2019 | $37.91M | -27.8% |
| Q2 FY2019 | Jun 30, 2019 | $47.36M | -24.3% |
| Q1 FY2019 | Mar 31, 2019 | $59.64M | -19.6% |
| Q4 FY2018 | Dec 31, 2018 | $41.50M | -52.4% |
| Q3 FY2018 | Sep 30, 2018 | $52.51M | -45.3% |
| Q2 FY2018 | Jun 30, 2018 | $62.59M | -41.0% |
| Q1 FY2018 | Mar 31, 2018 | $74.16M | +67.7% |
| Q4 FY2017 | Dec 31, 2017 | $87.13M | +67.7% |
| Q3 FY2017 | Sep 30, 2017 | $96.04M | +66.3% |
| Q2 FY2017 | Jun 30, 2017 | $106.12M | – |
| Q1 FY2017 | Mar 31, 2017 | $44.23M | – |
| Q4 FY2016 | Dec 31, 2016 | $51.94M | – |
| Q3 FY2016 | Sep 30, 2016 | $57.75M | – |
See a number that looks wrong?